Drs John Kane and Christoph U. Correll discuss the major metabolic and neurologic risks associated with antipsychotic medications for patients diagnosed with schizophrenia.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969525). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Schizophrenia https://www.medscape.com/resource/schizophrenia

Understanding the Effects of Antipsychotics on Appetite Control https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762106/

Food and Drug Administration's Obesity Drug Guidance Document https://www.ahajournals.org/doi/10.1161/circulationaha.111.028381

Risk of Weight Gain for Specific Antipsychotic Drugs: A Meta-analysis https://www.nature.com/articles/s41537-018-0053-9

Diabetes and Schizophrenia https://link.springer.com/article/10.1007/s11892-015-0704-4

Brain Insulin Action: Implications for the Treatment of Schizophrenia https://www.sciencedirect.com/science/article/abs/pii/S0028390819301960?via%3Dihub

Obesity as a Risk Factor for Accelerated Brain Ageing in First-Episode Psychosis -- A Longitudinal Study https://academic.oup.com/schizophreniabulletin/article-abstract/47/6/1772/6291438

Body Mass Index Identified as an Independent Predictor of Psychiatric Readmission https://pubmed.ncbi.nlm.nih.gov/25004198/#:~:text=Conclusions%3A%20Body%20mass%20index%20was,be%20explored%20in%20prospective%20studies

Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort https://pubmed.ncbi.nlm.nih.gov/30257079/

Incidence and Severity of Tardive Dyskinesia Increase With Age https://jamanetwork.com/journals/jamapsychiatry/article-abstract/492775

Extrapyramidal Symptoms With Atypical Antipsychotics: Incidence, Prevention and Management https://reference.medscape.com/medline/abstract/15733025

Drs John Kane and Stefan Leucht discuss the effectiveness and optimal dosing of antipsychotic medications in the treatment of schizophrenia.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969527). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Toward a Phenomenological Psychotherapy for Schizophrenia https://www.karger.com/Article/FullText/500163

APA Releases New Practice Guideline on Treatment of Patients with Schizophrenia https://www.psychiatry.org/newsroom/news-releases/apa-releases-new-practice-guideline-on-treatment-of-patients-with-schizophrenia

Pharmacological Treatments for First-Episode Schizophrenia https://academic.oup.com/schizophreniabulletin/article/31/3/705/1894509?login=false

Putting the Efficacy of Psychiatric and General Medicine Medication Into Perspective: Review of Meta-analyses https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/putting-the-efficacy-of-psychiatric-and-general-medicine-medication-into-perspective-review-of-metaanalyses/39C15F3428BDD1F8A4C152B67C06A5A6

The Nature of Relapse in Schizophrenia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599855

20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia https://pubmed.ncbi.nlm.nih.gov/29621900/

Amisulpride and Olanzapine Followed by Open-Label Treatment With Clozapine in First-Episode Schizophrenia and Schizophreniform Disorder (OPTiMiSE): A Three-Phase Switching Study https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(18)30252-9/fulltext

Clozapine https://reference.medscape.com/drug/clozaril-versacloz-clozapine-342972

Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study https://www.psychiatrist.com/jcp/schizophrenia/lurasidone-in-early-nonresponding-schizophrenia/

Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2019.19010034

Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2783296

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2725088

Drs John Kane and Jonathan M. Meyer discuss what new antipsychotic drugs are available for schizophrenia. What drugs are under development? And what do they potentially offer?

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969528). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

The Clozapine Handbook: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) New Edition https://www.amazon.com/Clozapine-Handbook-Handbooks-Essential-Psychopharmacology/dp/1108447465

The Clinical Use of Antipsychotic Plasma Levels: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) Kindle Edition https://www.amazon.com/Clinical-Antipsychotic-Plasma-Levels-Psychopharmacology-ebook-dp-B09B3VMM8N/dp/B09B3VMM8N

Clinical Use of Reserpine in Psychiatry: Comparison With Chlorpromazine https://nyaspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/j.1749-6632.1955.tb42463.x

Arvid Carlsson https://www.nobelprize.org/prizes/medicine/2000/carlsson/facts/

Clozapine: Guidelines for Clinical Management https://pubmed.ncbi.nlm.nih.gov/2670914/

Clozapine: Medscape Drugs & Diseases https://reference.medscape.com/drug/clozaril-versacloz-clozapine-342972

Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-analysis https://www.psychiatrist.com/jcp/movement-disorder/tardive-dyskinesia-prevalence/

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia — A Randomized Clinical Trial https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2758022

Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities https://pubs.acs.org/doi/10.1021/acsptsci.2c00016

Trace Amine-Associated Receptor 1 Modulates Dopaminergic Activity https://jpet.aspetjournals.org/content/324/3/948.long

A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia https://www.nejm.org/doi/10.1056/NEJMoa1911772

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia https://clinicaltrials.gov/ct2/show/NCT04109950

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms https://clinicaltrials.gov/ct2/show/NCT03669640

Emerging Schizophrenia Drugs Target Negative Symptoms https://www.medscape.com/viewarticle/953336

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2008.06091591

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia https://www.nejm.org/doi/10.1056/NEJMoa2017015

Risperidone, 2 mg/day vs. 4 mg/day, in First-Episode, Acutely Psychotic Patients: Treatment Efficacy and Effects on Fine Motor Functioning https://www.psychiatrist.com/jcp/schizophrenia/risperidone-mgday-vs-mgday-episode-acutely-psychotic/